The Impact of Strict Oversight on DTC Prescription Drug Ads

In September 2025, President Trump issued a statement pushing FDA to more strictly enforce existing regulations regarding DTC advertising for prescription drugs. At the time, the President’s memo argued that FDA was allowing too little information about the drugs to be included in the advertisements, leading in a rise in these sorts of ads.

HHS Secretary Kennedy has also highlighted his concerns with DTC prescription drug advertisements. At the time of the President’s statement, Secretary Kennedy issued a news release in which he said, ““Pharmaceutical ads hooked this country on prescription drugs. We will shut down that pipeline of deception and require drug companies to disclose all critical safety facts in their advertising. Only radical transparency will break the cycle of overmedicalization that drives America’s chronic disease epidemic.”

Since then, DTC advertisements have remained a talking point among the administration, but very little official action has been taken.

Dan Troy, currently a managing director and expert witness at Berkley Research Group and former lead counsel at FDA under previous administrations, spoke with Pharmaceutical Executive about the issues with regulating DTC advertisements. According to him, it might be harder to restrict these sorts of advertisements, which may not be having the negative impact officials have claimed.

Pharmaceutical Executive: What impact would strict oversight on prescription drug ads have on pharma companies?
Dan Troy: The question really is what kind of increased oversight there would be. There are constitutional limits on what government can do here. So, although the mandate from leadership called to ban DTC ads on TV and social media, that's just not possible given the First Amendment.

There's a grudging acknowledgement of that. I know that the lawyers at FDA and HHS understand the First Amendment constraints. So, obviously companies pay attention to what FDA does and says, but there are again very important limits on what FDA is going to be able to do in this space.